A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer
dc.contributor.author | Darendeliler, Emin | |
dc.contributor.author | Kizir, Ahmet | |
dc.contributor.author | Tuncel, Nina | |
dc.contributor.author | Oral, Ethem Nezih | |
dc.contributor.author | Karadeniz, Ahmet | |
dc.contributor.author | Bilge, Nijad | |
dc.contributor.buuauthor | Sarıhan, Süreyya | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı. | tr_TR |
dc.contributor.scopusid | 19837255600 | tr_TR |
dc.date.accessioned | 2021-10-22T22:56:00Z | |
dc.date.available | 2021-10-22T22:56:00Z | |
dc.date.issued | 1998 | |
dc.description.abstract | Purpose: A prospective phase II trial was conducted by the Institute of Oncology, istanbul University in December 1994 on patients with locally-advanced non-small cell lung cancer to assess acute toxicity and the feasibility of a combination of radiosensitizer and accelerated radiotherapy with concomitant boost. Materials and methods: Patients were irradiated using 'large' fields (primary tumour and locoregional lymph nodes) with 1.8 Gy per fraction, five fractions a week. Reduced 'boost' fields (primary and involved nodes only) were also irradiated twice-weekly 1.8 Gy per fraction in ten fractions concomitantly 6 h after the administration of large field. Total radiation dose was 63 Gy in 5 weeks (45 Gy 'large' fields and 18 Gy 'boost'). The maximum allowed dose to the spinal cord was 3750 cGy. Cisplatinum, 6 mg/m(2) was given daily just before 'large' field irradiation, Results: As of January1997, 15 patients were evaluated (median follow-up of 12.5 months with a range of 5.5-23 months). The overall acute toxicity rate was 38% and Grade 3 acute toxicity was 8%. Grade 4 or greater acute toxicities were not observed. The overall rate of cisplatinum-induced nausea and vomiting was 80% (severe in 60%), but all were easily treated with antiemetics. Complete response rate (clinical and radiological) was 40% and an overall response rate was 73%. Median survival was 16 months and progression-free survival was 5.5 months (range of 2.5-21 months). Conclusions: Toxicity was well tolerated and no treatment-related death occurred with this combined treatment regimen. Although it appears that better local control rates can be achieved, additional phase II/III studies are needed. | en_US |
dc.identifier.citation | Sarıhan, S. vd. (1998). "A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer". Lung Cancer, 20(1), 37-46. | en_US |
dc.identifier.endpage | 46 | tr_TR |
dc.identifier.issn | 0169-5002 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 9699186 | tr_TR |
dc.identifier.scopus | 2-s2.0-0031718511 | tr_TR |
dc.identifier.startpage | 37 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/S0169-5002(98)00003-8 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0169500298000038 | |
dc.identifier.uri | http://hdl.handle.net/11452/22450 | |
dc.identifier.volume | 20 | tr_TR |
dc.identifier.wos | 000074977000005 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ireland | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Lung Cancer | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject | Respiratory system | en_US |
dc.subject | Non-small cell lung cancer | en_US |
dc.subject | Concomitant boost | en_US |
dc.subject | Cisplatinum | en_US |
dc.subject | Radiosensitizer | en_US |
dc.subject | Therapy-oncology-group | en_US |
dc.subject | High-dose radiation | en_US |
dc.subject | Randomized trial | en_US |
dc.subject | Advanced head | en_US |
dc.subject | Fractionation schemes | en_US |
dc.subject | Tumor-control | en_US |
dc.subject | Neck-cancer | en_US |
dc.subject | Carcinoma | en_US |
dc.subject | Survival | en_US |
dc.subject | I/II | en_US |
dc.subject.emtree | Cisplatin | en_US |
dc.subject.emtree | Radiosensitizing agent | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer staging | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Lung non small cell cancer | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Nausea | en_US |
dc.subject.emtree | Phase 2 clinical trial | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Radiation dose | en_US |
dc.subject.emtree | Survival | en_US |
dc.subject.emtree | Vomiting | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Antineoplastic agents | en_US |
dc.subject.mesh | Carcinoma, non-small-cell lung | en_US |
dc.subject.mesh | Cisplatin | en_US |
dc.subject.mesh | Combined modality therapy | en_US |
dc.subject.mesh | Confidence intervals | en_US |
dc.subject.mesh | Dose fractionation | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lung neoplasms | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Prospective studies | en_US |
dc.subject.mesh | Radiation-sensitizing agents | en_US |
dc.subject.mesh | Radiotherapy | en_US |
dc.subject.mesh | Survival analysis | en_US |
dc.subject.scopus | Chemoradiotherapy; Consolidation Chemotherapy; Intensity Modulated Radiation Therapy | en_US |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Respiratory system | en_US |
dc.title | A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer | en_US |
dc.type | Article |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: